The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Dahiwadkar currently heads four technology companies- WipeOut Inc, Cognota Healthcare Technologies, IT Shastra India and Moringa Techsolv, which he has founded
Subscribe To Our Newsletter & Stay Updated
